Nufymco Q Code: Q5168

Drug & Product Overview

HCPCS Descriptor Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg

HCPCS Added Date July 1, 2026

Manufacturer Zydus Pharmaceuticals

Route of Administration Intravitreal

Generic Status Single-Source; Branded

Dosage Form Injection, Solution

About Nufymco

Nufymco is a medication aligned to the HCPCS Q Code: Q5168 for billing, pricing, and reimbursement purposes in the United States. This Ophthalmology medication is administered via the intravitreal route and manufactured by Zydus Pharmaceuticals.

Manufacturers, reach out to us to add more information.

NDC Code Information

Based on publicly available CMS files. Showing 1 of 2 NDCs — log in for the full crosswalk.

NDC Code	Drug	Manufacturer	Billing Units / Pkg	Package Size
70710-2173-01	Nufymco	Zydus Pharmaceuticals USA Inc.	5	0.5 MG / 0.05 ML
•••••-••••-•• Log in to view	Nufymco

Login to view 1 more NDC package View pricing, complete NDC-to-HCPCS alignments, and package details.

Login →

Nufymco Pricing & Reimbursement

Historical Graphing and Billing Calculator

per HCPCS unit

As of Q4 2026

Ranibizumab Biosimilar Information:

Nufymco Approval Date: December 18, 2025

Product Name	HCPCS Code	Active Ingredient	BLA Type
Lucentis	J2778	Ranibizumab	351(a) Originator Product
Byooviz	Q5124	Ranibizumab	351(k) Interchangeable
Cimerli	Q5128	Ranibizumab	351(k) Interchangeable
Nufymco	Q5168	Ranibizumab	351(k) Interchangeable
Ranluspec	N/A	Ranibizumab	351(k) Interchangeable
Lucamzi	N/A	Ranibizumab	351(k) Biosimilar

One of 5 Lucentis biosimilars FDA-approved since 2021 See each approval by month on the BuyandBill.com Pipeline calendar. Comes with Pro. Every ranibizumab approval, month by month.

Try a sample month → Open in Pipeline →

Nufymco CPT Administration Codes

CPT Code	Description
67028	Intravitreal injection of a pharmacologic agent (separate procedure) 67028

Not on the CMS JW / JZ list

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers. Wastage billing guide →

Nufymco Clinical Information

Indications and drug classification.

Treated Diseases & Conditions

This list of indications is not exhaustive and may be subject to errors. The information on BuyandBill.com is intended for informational purposes only and should not be used for medical advice.

Diabetic Macular Edema (DME) Diabetic Retinopathy (DR) Macular Edema Following Retinal Vein Occlusion (RVO) Myopic Choroidal Neovascularization (mCNV) Neovascular (Wet) Age-Related Macular Degeneration (AMD)

Drug Class

Vascular Endothelial Growth Factor Inhibitor [EPC]Vascular Endothelial Growth Factor Inhibitors [MoA]

Frequently Asked Questions

Is there an available Nufymco billing and coding guide?

A manufacturer-published billing and coding guide for NUFYMCO was not found.

Are there any available Nufymco patient assistance programs?

No manufacturer-published NUFYMCO patient assistance link was found.

Where can I find Nufymco prescribing information?

No NUFYMCO prescribing information link was found.

Where can I find Nufymco side effect information?

Information regarding NUFYMCO's side effects can be found at MedlinePlus Visit Here →

Does billing NUFYMCO require JZ/JW wastage modifiers?

This product is new and does not yet appear on the CMS list of HCPCS pertaining to single-dose containers.

About BuyandBill.com:

The BuyandBill.com team is dedicated to delivering high-quality coding and billing information for office-administered drugs. We continuously research HCPCS-coded medications to expand our resources and ensure data accuracy. Manufacturers: click here to sponsor your medication, and we will ensure the most accurate and detailed information is displayed.